Jump to content

Ellinor Peerschke

Add links
From Wikipedia, the free encyclopedia
(Redirected from Draft:Ellinor Peerschke)
Ellinor Peerschke
Born1954 (1954)
Braunschweig, West Germany
Died2023 (aged 68–69)
Academic background
Alma mater

Ellinor Peerschke (May 7, 1954-October 13, 2023)[1] was an American scientist specializing in coagulation, complement, and platelet biology.

Early life and education

[edit]

Peerschke was born in Braunschweig, Germany. She grew up in New Jersey, graduated from Rutgers and earned her PhD from New York University in 1980, studying under Dr. Marjorie Zucker.[2]

Career

[edit]

Peerschke held faculty positions at SUNY Stony Brook, Weill Cornell Medicine, Icahn School of Medicine at Mount Sinai, and Memorial Sloan Kettering. At Memorial Sloan Kettering, she was Vice Chair for Research, Education and Development in the Department of Laboratory Medicine. She directed the hospital hematology and coagulation laboratories[3] and shaped international guidelines on laboratory diagnosis[4][5][6][7][8] and treatment of bleeding and clotting disorders.[9][10]

Peerschke worked with Barry Coller to establish how the binding of fibrinogen to Glycoprotein IIb/IIIa is necessary for platelet aggregation. Their work on the resulting complexes, along with monoclonal antibodies she helped develop, led to numerous therapeutics used for cardiovascular disease.[2]

Joining with her husband Dr. Berhane Ghebrehiwet, Peerschke went on to map the interactions of platelets with complement component C1q. Their discoveries built a framework to understand the pathophysiology of pathogen-associated molecular patterns in HIV,[11] hepatitis C,[12] immune thrombocytopenia,[13][14] and COVID-19.[15][16]

Peerschke studied both the collagen-like tail region of C1q, which binds calreticulin, and the receptor for the globular head of C1q, known as gC1qR. Her work on the binding of gC1qR to high-molecular-weight kininogen and coagulation factor XII helped elucidate how the kinin–kallikrein system generates bradykinin, thus advancing knowledge in coagulation,[17][18] inflammation,[19] infection,[20] lupus,[21][22] and cancer.[23][24][25]

Peerschke developed programs for undergraduate and postgraduate medical education in the diagnosis of blood disorders.[26][27][28][29][30] She contributed to laboratory stewardship efforts which are part of reducing unnecessary health care.[31] She was president of the Academy of Clinical Laboratory Physicians and Scientists and vice president of the North American Specialized Coagulation Laboratory Association (NASCOLA). She served on the ASH education committee, AHA thrombosis study group, NHLBI project review committee, and ISTH international advisory board.[3]

Awards

[edit]

Gerald T. Evans Award, Academy of Clinical Laboratory Physicians and Scientists, 2011[32]

Selected articles

[edit]
  • Peerschke EI, Zucker MB. Fibrinogen receptor exposure and aggregation of human blood platelets produced by ADP and chilling. Blood. 1981;57:663–70.
  • Peerschke EI, Grant RA, Zucker MB. Decreased association of 45calcium with platelets unable to aggregate due to thrombasthenia or prolonged calcium deprivation. Br J Haematol. 1980;46:247–56.
  • Peerschke EI. Induction of human platelet fibrinogen receptors by epinephrine in the absence of released ADP. Blood. 1982;60:71–7.
  • Peerschke EI. Evidence for interaction between platelet fibrinogen receptors. Blood. 1982;60:973–8.
  • Peerschke EI, Wainer JA. Examination of irreversible platelet-fibrinogen interactions. Am J Physiol. 1985;248:C466–72.
  • Peerschke EI. Decreased accessibility of platelet-bound fibrinogen to antibody and enzyme probes. Blood. 1989;74:682–9.
  • Peerschke EI, Francis CW, Marder VJ. Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood. 1986;67:385–90.
  • Peerschke EI, Galanakis DK. The synthetic RGDS peptide inhibits the binding of fibrinogen lacking intact alpha chain carboxyterminal sequences to human blood platelets. Blood. 1987;69:950–2.
  • Peerschke EI. Bound fibrinogen distribution on stimulated platelets. Examination by confocal scanning laser microscopy. Am J Pathol. 1995;147:678–87.
  • Peerschke EI. Maintenance of GPIIb-IIIa avidity supporting "irreversible" fibrinogen binding is energy-dependent. J Lab Clin Med. 1999;134:398–404.
  • Peerschke EI. Reversible and irreversible binding of fibrinogen to platelets. Platelets. 1997;8:311–7.
  • Peerschke EI, Ghebrehiwet B. Human blood platelets possess specific binding sites for C1q. J Immunol. 1987;138:1537–41.
  • Peerschke EI, Ghebrehiwet B. Identification and partial characterization of human platelet C1q binding sites. J Immunol. 1988;141: 3505–11.
  • Peerschke EI, Reid KB, Ghebrehiwet B. Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med. 1993;178:579–87.
  • Peerschke EI, Reid KB, Ghebrehiwet B. Identification of a novel 33-kDa C1q-binding site on human blood platelets. J Immunol. 1994;152:5896–901.

References

[edit]
  1. ^ "Obituary information for Ellinor Peerschke". www.bryantfh.com. Retrieved 2024-10-14.
  2. ^ a b Coller BS, Ghebrehiwet B, Pessin M (March 2024). "Ellinor Peerschke, PhD (1954-2023)". J Thromb Haemost. 22 (3): 889–891. doi:10.1016/j.jtha.2023.12.011. PMID 38104722.
  3. ^ a b "Ellinor Peerschke (1954-2023)". International Complement Society. Retrieved 13 October 2024.
  4. ^ Fenelus M, Peerschke EI (July 2018). "HITTING the Diagnosis: Testing for Heparin-Induced Thrombocytopenia in Cancer Patients". Am J Clin Pathol. 150 (2): 116–120. doi:10.1093/ajcp/aqy040. PMC 6049042. PMID 29901688.
  5. ^ Chandler WL, Peerschke EI, Castellone DD, Meijer P (June 2011). "Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience". Am J Clin Pathol. 135 (6): 862–9. doi:10.1309/AJCPH5JK4ONENPAE. PMID 21571959.
  6. ^ Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI (November 2010). "Lupus anticoagulant testing: performance and practices by north american clinical laboratories". Am J Clin Pathol. 134 (5): 764–73. doi:10.1309/AJCP4SPPLG5XVIXF. PMID 20959659.
  7. ^ Dembitzer FR, Suarez Y, Aledort LM, Peerschke EI (September 2010). "Screening coagulation testing using the APTT: which reagent to choose?". Am J Hematol. 85 (9): 726. doi:10.1002/ajh.21780. PMID 20645431.
  8. ^ Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P (April 2009). "Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience". Am J Clin Pathol. 131 (4): 552–8. doi:10.1309/AJCPMKP94CODILWS. PMID 19289591.
  9. ^ Frontera JA, Lewin JJ, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, Del Zoppo GJ, Kumar M, Peerschke EI, Stiefel MF, Teitelbaum JS, Wartenberg KE, Zerfoss CL (December 2016). "Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine". Crit Care Med. 44 (12): 2251–2257. doi:10.1097/CCM.0000000000002057. PMID 27858808.
  10. ^ Fritsma GA, Dembitzer FR, Randhawa A, Marques MB, Van Cott EM, Adcock-Funk D, Peerschke EI (June 2012). "Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization". Am J Clin Pathol. 137 (6): 904–8. doi:10.1309/AJCP3J1ZKYBFQXJM. PMID 22586049.
  11. ^ Pednekar L, Valentino A, Ji Y, Tumma N, Valentino C, Kadoor A, Hosszu KK, Ramadass M, Kew RR, Kishore U, Peerschke EI, Ghebrehiwet B (June 2016). "Identification of the gC1qR sites for the HIV-1 viral envelope protein gp41 and the HCV core protein: Implications in viral-specific pathogenesis and therapy". Mol Immunol. 74: 18–26. doi:10.1016/j.molimm.2016.03.016. PMC 4987126. PMID 27111569.
  12. ^ Sansonno D, Tucci FA, Ghebrehiwet B, Lauletta G, Peerschke EI, Conteduca V, Russi S, Gatti P, Sansonno L, Dammacco F (November 2009). "Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage". J Immunol. 183 (9): 6013–20. doi:10.4049/jimmunol.0902038. PMC 2794553. PMID 19828637.
  13. ^ Peerschke EI, Andemariam B, Yin W, Bussel JB (February 2010). "Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura". Br J Haematol. 148 (4): 638–45. doi:10.1111/j.1365-2141.2009.07995.x. PMC 5004348. PMID 19925495.
  14. ^ Peerschke EI, Panicker S, Bussel J (June 2016). "Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor". Br J Haematol. 173 (6): 942–5. doi:10.1111/bjh.13648. PMC 4973859. PMID 26305671.
  15. ^ Peerschke EI, Valentino A, So RJ, Shulman S, Ravinder (2021). "Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19". Front Immunol. 12: 716361. doi:10.3389/fimmu.2021.716361. PMC 8416543. PMID 34491250.
  16. ^ Ghebrehiwet B, Peerschke EI (November 2020). "Complement and coagulation: key triggers of COVID-19-induced multiorgan pathology". J Clin Invest. 130 (11): 5674–5676. doi:10.1172/JCI142780. PMC 7598033. PMID 32925166.
  17. ^ Bussel JB, Peerschke E (October 2021). "Heritable platelet disorders: an enigma even guidelines can't unravel". Br J Haematol. 195 (1): 13–14. doi:10.1111/bjh.17809. PMID 34494258.
  18. ^ Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B (September 2006). "Blood platelets activate the classical pathway of human complement". J Thromb Haemost. 4 (9): 2035–42. doi:10.1111/j.1538-7836.2006.02065.x. PMID 16961611.
  19. ^ Peerschke EI, Yin W, Ghebrehiwet B (August 2010). "Complement activation on platelets: implications for vascular inflammation and thrombosis". Mol Immunol. 47 (13): 2170–5. doi:10.1016/j.molimm.2010.05.009. PMC 2904326. PMID 20621693.
  20. ^ Ghebrehiwet B, Jesty J, Vinayagasundaram R, Vinayagasundaram U, Ji Y, Valentino A, Tumma N, Hosszu KH, Peerschke EI (2013). "Targeting gC1qR domains for therapy against infection and inflammation". Complement Therapeutics. Adv Exp Med Biol. Vol. 735. pp. 97–110. doi:10.1007/978-1-4614-4118-2_6. ISBN 978-1-4614-4117-5. PMID 23402021.
  21. ^ Ghebrehiwet B, Hosszu KK, Valentino A, Ji Y, Peerschke EI (2014). "Monocyte Expressed Macromolecular C1 and C1q Receptors as Molecular Sensors of Danger: Implications in SLE". Front Immunol. 5: 278. doi:10.3389/fimmu.2014.00278. PMC 4071343. PMID 25018754.
  22. ^ Hosszu KK, Valentino A, Peerschke EI, Ghebrehiwet B (2020). "SLE: Novel Postulates for Therapeutic Options". Front Immunol. 11: 583853. doi:10.3389/fimmu.2020.583853. PMC 7575694. PMID 33117397.
  23. ^ Peerschke EI, Stanchina E, Chang Q, Manova-Todorova K, Barlas A, Savitt AG, Geisbrecht BV, Ghebrehiwet B (October 2020). "Anti gC1qR/p32/HABP1 Antibody Therapy Decreases Tumor Growth in an Orthotopic Murine Xenotransplant Model of Triple Negative Breast Cancer". Antibodies (Basel). 9 (4): 51. doi:10.3390/antib9040051. PMC 7709104. PMID 33036212.
  24. ^ Peerschke E, Stier K, Li X, Kandov E, de Stanchina E, Chang Q, Xiong Y, Manova-Todorova K, Fan N, Barlas A, Ghebrehiwet B, Adusumilli PS (2020). "gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma". Front Oncol. 10: 1413. doi:10.3389/fonc.2020.01413. PMC 7435067. PMID 32903438.
  25. ^ Peerschke EI, Ghebrehiwet B (October 2014). "cC1qR/CR and gC1qR/p33: observations in cancer". Mol Immunol. 61 (2): 100–9. doi:10.1016/j.molimm.2014.06.011. PMID 25044096.
  26. ^ Kessler C, Peerschke EI, Chitlur MB, Kulkarni R, Holot N, Cooper DL (April 2017). "The Coags Uncomplicated App: Fulfilling Educational Gaps Around Diagnosis and Laboratory Testing of Coagulation Disorders". JMIR Med Educ. 3 (1): e6. doi:10.2196/mededu.6858. PMC 5413799. PMID 28420603.
  27. ^ Magid MS, Shah DT, Cambor CL, Conran RM, Lin AY, Peerschke EI, Pessin MS, Harris IB (2015). "Consensus Guidelines for Practical Competencies in Anatomic Pathology and Laboratory Medicine for the Undifferentiated Graduating Medical Student". Acad Pathol. 2 (4): 2374289515605336. doi:10.1177/2374289515605336. PMC 5479462. PMID 28725750.
  28. ^ Luning Prak ET, Young DS, Kamoun M, Nachamkin I, Alexander CB, Spitalnik SL, Peerschke EI, Smith BR (May 2009). "2008 ACLPS panel discussion on resident education in clinical pathology". Am J Clin Pathol. 131 (5): 618–22. doi:10.1309/AJCPPI03HMYAAEOJ. PMID 19369619.
  29. ^ Peerschke EI, Agrawal Y, Alexander CB, Bovill E, Laposata M (June 2007). "Proposed research training guidelines for residents in laboratory medicine". Clin Lab Med. 27 (2): 241–53, abstract v–vi. doi:10.1016/j.cll.2007.03.002. PMID 17556083.
  30. ^ Smith BR, Wells A, Alexander CB, Bovill E, Campbell S, Dasgupta A, Fung M, Haller B, Howe JG, Parvin C, Peerschke E, Rinder H, Spitalnik S, Weiss R, Wener M (August 2006). "Curriculum content and evaluation of resident competency in clinical pathology (laboratory medicine): a proposal". Hum Pathol. 37 (8): 934–68. doi:10.1016/j.humpath.2006.01.034. PMID 16867855.
  31. ^ Fenelus M, Graham T, Golden R, Bautista JL, So RJ, Plante N, Peerschke EI (March 2021). "Choosing wisely during the COVID-19 pandemic: optimising outpatient cancer care while conserving resources with a new algorithm to report automated ANC results". J Clin Pathol. 74 (3): 202–204. doi:10.1136/jclinpath-2020-207114. PMC 8300857. PMID 33199298.
  32. ^ "Previous Award Winners". ACLPS. Retrieved 13 October 2024.
[edit]

Biography

Retrieved from "https://wiki.riteme.site/w/index.php?title=Ellinor_Peerschke&oldid=1256897306"